Fujirebio
Fujirebio Files Blood-Based Alzheimer's Test With FDA
The test measures levels of p-tau 217 and β-Amyloid 1-42 in human plasma to identify patients with the amyloid brain pathology characteristic of Alzheimer's disease.
Davos Alzheimer's Collaborative Creates Initiative to Improve Alzheimer's Diagnosis
Under the program, blood biomarkers and confirmatory diagnostic testing will be used to increase diagnosis of Alzheimer’s disease and related dementias.
Two studies, led by researchers at Oxford and University College London, aim to explore whether blood-based markers can speed up diagnoses and improve outcomes.
Abbott, Fujirebio Partner on Neurology Biomarker Assay
The companies are developing a research-use-only test for neurofilament-light chain for use on Abbott's Alinity I instrument.
Many firms in the space have developed or are developing tests for the marker, which shows great promise for detecting brain amyloid pathology.